Navigation Links
Questcor Reports Record Second Quarter Financial Results
Date:7/24/2014

215 and 220 new paid prescriptions for Infantile Spasms during the quarter, compared to between 215 to 220 new paid prescriptions for Infantile Spasms in the year ago quarter.  

The Company believes that insurance coverage for Acthar continues to remain favorable and relatively consistent.  The Company believes that reimbursement rates for Acthar have remained favorable and relatively consistent in large part because Acthar is generally reserved by physicians for patients with more severe forms of the medical conditions for which the drug is being prescribed, the patient has often not properly responded to other therapies and Acthar is approved by the FDA for that difficult to treat medical condition.

Year-to-Date Financial ResultsNet sales for the first six months of 2014 were $505.9 million, with BioVectra contributing $34.8 million. Net sales in the first six months of 2013 were $319.7 million, with BioVectra contributing $15.9 million. On a non-GAAP basis, net sales for the six months ended June 30, 2013 were $331.2 million.  GAAP earnings for the first six months of 2014 were $2.75 per diluted common share, compared to $1.79 per diluted common share for the comparable period of 2013. Non-GAAP earnings for the six months ended June 30, 2014 were $3.25 per diluted common share excluding non-cash share-based compensation expense, depreciation and amortization expense, other non-cash expense related to the acquisitions of BioVectra and Synacthen and Synacthen Depot, and transaction-related expenses in connection with our pending merger with Mallinckrodt public limited company (NYSE: MNK). Non-GAAP earnings for the comparable period of 2013 were $2.13 per diluted common share. The reconciliation between GAAP and non-GAAP financial measures is provided with the financial tables included with this release.

Research and Development ProgressResearch and development (R&D) expense increased 80% to $22.0 million in the three months e
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related medicine technology :

1. Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Provide Update On Transaction
2. Questcor Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
3. Products Recall, Stock Price Updates, Technology Solution Deployment, Update on Extension Trial, and Donations - Research Report on Alexion Pharma, Questcor, BioMarin Pharma, Allscripts, and Prana
4. Questcor Provides Donation In Support Of Childrens Hospital & Research Center Oakland
5. Partnerships, Appointments, New Products, Public Offerings, and Agreements - Research Report on Questcor Pharmaceuticals, Hologic, IDEXX, Endologix, and Healthways
6. Questcor Announces Quarterly Cash Dividend and Provides Update on Share Repurchase Program
7. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
8. Biologics License Applications, Event Participations, and Stock Movements - Research Report on Baxter, WellPoint, Questcor Pharmaceuticals, CareFusion, and Hologic
9. Product Reviews, Recognitions, FDA Responses, and New Leadership Appointments - Research Report on Gilead, WellPoint, Questcor, Forest Laboratories, and Envision Healthcare
10. Questcor Honored as an "Everyday Hero" by NephCure Foundation
11. Questcor Adds G. Kelly Martin to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 On September 25 to 26, ... on medical design and manufacturing - MEDTEC China  - ... Expo Exhibition & Convention Center, bringing together close to ... to showcase their latest medical-grade raw materials, parts and ... week remaining for free visitor pre-registration to be completed. ...
(Date:9/16/2014)... Sept. 16, 2014 The Lupus Foundation of ... LLY ) today released results from UNVEIL: understanding the ... on the lupus journey and the challenges not only ... caregivers. The UNVEIL study, which involved over 1,000 people ... lupus has on all aspects of life including family, ...
(Date:9/16/2014)... HOUSTON , Sept. 16, 2014  DNAtrix, ... that the first patient was treated with the ... plus gamma interferon in a randomized, multicenter, open-label ... "DNAtrix, in collaboration with leading neurosurgeons ... announce the initiation of our randomized Phase Ib ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... Scientists from the Barbara Ann Karmanos Cancer Institute in ... therapeutic agents used to promote bone health and inhibit resorption, ... with early stage breast cancer who take them for their ... American Society of Clinical Oncology Annual Meeting. , ...
... Abviva, Inc. (Pink Sheets: ABVV), a biomedical company engaged in ... today provided further details about worldwide patent protection for its breast ... , , ... as its independent auditor.  Abviva is working hard to regain compliance ...
Cached Medicine Technology:Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 2Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 3Karmanos Cancer Institute Researchers Study Bisphosphonates and Their Affect on Early Stage Breast Cancer 4Abviva Engages W.T. Uniack & Co. As Independent Auditor 2
(Date:9/16/2014)... 2014 An experienced review website, ... and announced that Bluehost and HostGator.com are among ... want to purchase high quality web hosting (including ... visit their websites now. , BlueHost ( ... established itself as a reliable and long-standing force ...
(Date:9/16/2014)... Pulmonary Hypertension Association Travels to San Diego for ... Patients and Families to Help Fight Rare Lung Disease , ... pulmonary hypertension association that works to find ways to prevent ... lungs that affects the functioning of the heart and can ... only 2.8 years. , What:, PHA On The ...
(Date:9/16/2014)... (PRWEB) September 17, 2014 ... hosting suppliers from the USA and announces ... ) are the best Windows web hosting ... on offering worldwide clients high quality WordPress ... low rates. , HostMonster provides outstanding ...
(Date:9/16/2014)... HealthDay Reporter TUESDAY, Sept. 16, 2014 ... human papillomavirus (HPV), which is linked to the risk of ... that testing urine for HPV has good accuracy when compared ... lead researcher Dr. Neha Pathak. She is a resident in ... of London, England. The test could be done at ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. ... as one of the Top Doctors of 2014. The ... metropolitan magazine serving the Houston area. They award esteemed ... their outstanding services. This accomplishment will be included in ... — a special publication listing all the winners of ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com: BlueHost and HostGator.com Are Among the Best Hosting Suppliers in 2014 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Travels to San Diego for PHA On The Road to Help Fight Rare Lung Disease 3Health News:Best Windows Web Hosting Suppliers Recommended By SEO Hosting Review Site Top10BestSEOHosting.com 2Health News:Urine Test for HPV Works Well, Analysis Finds 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2
... Modifying gene called Foxp3 may develop cells capable of ... -- New understanding about how to control autoimmune responses ... arthritis (RA), British researchers say. , RA -- a ... body,s immune system attacks itself. A molecule called Foxp3 ...
... financial, operational, and clinical visibility to ... ... Fla., Nov. 13 Sentry Data Systems,today announced HealthBIT, a ... and clinical,visibility to hospitals by qualifying, aggregating, and comparing their,data ...
... Found with Free, Online Resources -, White ... paying out-of-pocket to fill prescriptions, and with those ... "Safe,Strategies for Drug Savings" today on its site ... in the U.S., Canada, and other,countries as well, ...
... Access to the Power of the Xevo TQ System,s Quantitative ... ... MILFORD, Mass., Nov. 13 Focused on the,process of helping firms ... ) will showcase innovative,UltraPerformance LC(R) (UPLC) and mass spectrometry (MS) solutions ...
... suite enables payors to compete like ... evolving healthcare marketplace, BURLINGTON, Mass., Nov. 13 ... platform for healthcare payors,today announced that it will ... 2008 Gartner Healthcare Summit. The,conference will be held ...
... Patients with advanced non-small cell lung cancer whose ... rate of tumor shrinkage and a longer interval ... standard second-line erlotinib therapy, according to a study ... Thoracic Oncology, sponsored by ASTRO, ASCO, IASLC and ...
Cached Medicine News:Health News:New Therapy Could Transform Arthritis Treatment 2Health News:Sentry Data Systems Announces Healthcare Business Intelligence Technology Platform 2Health News:PharmacyChecker.com Publishes 'Safe Strategies for Drug Savings' to Help All Americans Get Affordable Medication 2Health News:Waters To Unveil Xevo TQ MS Applications for Improved Drug Discovery at AAPS 2008 2Health News:Waters To Unveil Xevo TQ MS Applications for Improved Drug Discovery at AAPS 2008 3Health News:HealthEdge(R) Presents Award-Winning HealthRules(R) Technology Platform at the 2008 Gartner Healthcare Summit 2
80 inch PVC tubing with connectors and 19 gauge straight, beveled cannula. Fits Bausch & Lomb Surgical cassettes. Allows the safe removal of silicone oil in 10 minutes or less. 3/Box...
... gauge, 25 mm cannula with 30 gauge, 4.76 ... mm flattened tip. Cannula is attached to a ... ID x 8 inch long), for use with ... other vitreo-retinal membranes using visco elastic materials. Flattened, ...
20 gauge x 25 mm cannula with 30 degree x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub. 10 per box....
Developed for oculoplastic procedures for corneal and scleral protection. Dimensions enable protector to rest on the sclera and not on the cornea. Easily removed with Bishop-Harmon Forceps. Individua...
Medicine Products: